NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Fezolinetant for treating moderate to severe vasomotor symptoms associated with the menopause ID5071

Final Stakeholder List

Provisional consultees	Provisional commentators (no right to submit or appeal)
Company • Astellas Pharma (fezolinetant) Patient/carer groups • Daisy Network • Hysterectomy Association • Independent Cancer Patients' Voice • The Menopause Charity • Menopause Matters • Menopause UK • Menopause and Cancer • Queer Menopause Collective • South Asian Health Foundation • Specialised Healthcare Alliance • Wellbeing of Women • Women's Health Concern Healthcare professional groups • British Geriatrics Society • British Gynaecological Cancer Society • British Menopause Society • Faculty of Sexual & Reproductive Healthcare • Primary Care Women's Health Forum • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians & Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • UK Clinical Pharmacy Association Others • Department of Health and Social Care	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Comparator companies **HRT** • ADVANZ Pharma (tibolone) • Artisto Pharma (tibolone) • Bayer (oestrogen) • Besins Healthcare (UK) (combined oestrogen/progesterone) • Gedeon Richter UK (oestrogen) • Merus Labs Luxco II S.à R.L. (oestrogen) • Mylan (oestrogen, combined oestrogen and progesterone) • Novartis (oestrogen) • Novo Nordisk (combined oestrogen and progesterone)

Provisional consultees	Provisional commentators (no right to submit or appeal)
• NHS England	• Orion (oestrogen, combined oestrogen and progesterone) • Organon Phama UK (tibolone) • Pfizer (oestrogen, combined oestrogen and progesterone) • Strides Pharma UK (tibolone) • Theramex UK (oestrogen, progesterone, combined oestrogen and progesterone) **Anti-depressants (SSRIs, SNRIs)** • A. Menarini Farmaceutica Internazionale SRL (dapoxetine) • Accord Healthcare (citalopram, escitalopram, fluoxetine, paroxetine, sertraline) • Accord UK (citalopram, fluoxetine, paroxetine) • ADVANZ Pharma (citalopram, fluoxetine, venlafaxine) • Amarox (citalopram, duloxetine) • Amdipharm (citalopram, venlafaxine) • Aspire Pharma (duloxetine, venlafaxine) • Aurobindo Pharma-Milpharm (citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine) • Bristol Laboratories (venlafaxine) • Brown & Burk UK (escitalopram, fluoxetine) • Cipla EU (fluoxetine) • Dexcel Pharma (venlafaxine) • Dr Reddy's Laboratory (duloxetine, fluoxetine, sertraline) • Eli Lilly and Company (duloxetine) • Endo Ventures (fluoxetine) • Fannin UK (fluoxetine) • Flamingo Pharma (fluoxetine, sertraline) • GlaxoSmithKline (paroxetine) • Glenmark Pharmaceuticals Europe (escitalopram) • Krka UK (venlafaxine) • Lundbeck (citalopram, escitalopram, vortioxetine)

Provisional consultees	Provisional commentators (no right to submit or appeal)
	• Lupin Healthcare (sertraline) • Martindale Pharma, an Ethypharm Group Company (venlafaxine) • Morningside Healthcare (paroxetine, venlafaxine) • Mylan (dapoxetine, fluvoxamine, fluoxetine, sertraline) • Neuraxpharm UK (duloxetine) • Pinewoord Healthcare (fluoxetine) • Ranbaxy Ltd (Sun Pharma) (sertraline, venlafaxine) • Rivopharm UK (citalopram) • Rosemont Pharmaceuticals (fluoxetine, venlafaxine) • Sandoz (citalopram, paroxetine) • Thame Laboratories (citalopram) • Tillomed Laboratories (venlafaxine) • Viatris (sertraline, venlafaxine) • Zentiva (citalopram, sertraline) • Zentiva (duloxetine) **Clonidine** • Sandoz • Syri **Anti-convulsants** • ADVANZ Pharma (pregabalin) • Amarox (gabapentin, pregabalin) • Aristo Pharma (pregabalin) • Aspire Pharma (pregabalin) • Aurobindo Pharma - Milpharm (gabapentin, pregabalin) • Brown & Burk UK (gabapentin, pregabalin) • Colonis Pharma (gabapentin) • Dr Reddy's Laboratories (UK) (pregabalin) • Glenmark Pharmaceuticals Europe (gabapentin) • MSN Laboratories Europe (pregabalin) • Mylan (pregabalin) • Neuraxpharm UK (pregabalin) • Northumbria Pharma (pregabalin) • Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Provisional consultees	Provisional commentators (no right to submit or appeal)
	(pregabalin) • Rivopharm UK (gabapentin) • Rosemont Pharmaceuticals Limited (gabapentin, pregabalin) • Sandoz Limited (pregabalin) • Strides Pharma UK (gabapentin) • Thame Laboratories (gabapentin) • Tillomed Laboratories (gabapentin, pregabalin) • Viatris (gabapentin, pregabalin) • Wockhardt UK (pregabalin) • Zentiva (pregabalin) <u>Relevant research groups</u> • Cochrane Menstrual Disorders and Subfertility Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • Nottingham Clinical Trials Unit <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:
Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts, and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

